Erythromycin
Brand: Erycin (US/EU) / Erythrocin (IN/BD)
Antibiotic
Macrolide
Pharmacokinetics
| Half-life | 1.5 hours |
| Tmax | 2 h |
| Bioavailability | 30 % (approx) |
| Protein Binding | 80 % |
| Volume of Distribution | 0.5 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Strong CYP3A4 inhibitor; most GI side effects among macrolides due to motilin receptor agonism. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Severe GI upset, QT prolongation, hepatotoxicity
Contraindications:
History of torsades or congenital long QT
Precautions:
Avoid co-administration with other QT prolonging drugs; avoid in significant hepatic dysfunction